View all conferences
Jul 26 - 28, 2022

Gamma Delta T Cell Summit, Boston

Dr. James Lederer

Our CSO, Dr. James Lederer, presented at the pre-conference deep dive day on the 26th on the topic ‘Studying the Mechanisms of Action of Polyfunctional Gamma Delta T Cells’. By all reports, it’s an excellent meeting with great ideas circulating and lots to learn.

Synopsis of Dr. Lederer’s presentation:

  • Outlining known, and thus far unconfirmed  but hypothesized, mechanisms of
  • gamma delta T cell action
  • Understanding how to activate gamma delta T cell subsets and stimulate
  • cytotoxic mechanisms
  • Investigating their interaction with endogenous cells
  • Highlighting the key drivers of cytoxicity of gamma delta cells and what drives
  • killing, such as TCRs of NK-like cells
  • Defining the phenotype of a cytotoxic gamma delta T cell
  • Identifying checkpoints on gamma delta T cells to modulate function
  • Mapping the mechanisms by which gamma delta T cells recognize stressed vs. non-stressed tissue, vs. NK cell identification of self vs. non-self.

 

Dr. Frank Borriello

On Thursday 28th July 2022, Alloplex’s Founder and CEO, Dr. Frank Borriello spoke at the 3rd Gamma Delta T Therapies Summit in a session titled ‘Reviewing the clinical safety and efficacy of gamma delta therapies’ on the Response in Solid Tumors of Non-Engineered Autologous Multi-Cell Therapy.

Synopsis of Dr. Borriello’s presentation:

  • Outlining the genesis of a multimodal cellular therapy called SUPLEXA
  • Investigating the clinical mechanism of action of multi-modal cellular therapy in coordinating an anti-tumor response
  • Developing an exploratory research program with clinical samples to study this autologous therapy
  • Outlining the clinical observations to date.

 

About the summit:

As newly published data show the first Gamma Delta T cell therapy’s clinical efficacy in patients, the race to market for the first allogeneic and solid tumor-targeting γδT has begun.

The 3rd Gamma Delta T Therapies Summit brought together 120+ of the world’s leaders in the field to discuss discovery to manufacturing and clinical development of these ‘holy grail’ therapies in allogeneic and solid tumor settings.

The meeting of with industry pioneers harnessing GDT cells to bring to market more cytotoxic, clinically safe therapies for solid tumor allowed participants to engage in interactive discussions and gain the actionable insights to advance bench to commercial bedside development of γδT-based therapies.